Document is current
Any future updates will be listed below
-
Authors
Fearey, Brenna C. https://orcid.org/0000-0002-2649-7727
Binkle, Lars https://orcid.org/0000-0001-6168-3210
Mensching, Daniel
Schulze, Christian
Lohr, Christian https://orcid.org/0000-0001-6518-6422
Friese, Manuel A. https://orcid.org/0000-0001-6380-2420
Oertner, Thomas G. https://orcid.org/0000-0002-2312-7528
Gee, Christine E. https://orcid.org/0000-0003-0345-3665
-
Funding
Funding for this research was provided by:
Deutscher Akademischer Austauschdienst (57214224)
Landesforschungsforderung, Hamburg, Germany
Deutsche Forschungsgemeinschaft (335447717, 335447717, 335447717, 335447717)
- License Information
-
More Information
Article History
Received: 31 August 2021
Accepted: 16 March 2022
First Online: 9 April 2022
Competing interests
: MAF is a co-applicant on patents for using TRPM4 as a drug target. All other authors declare no competing interests.
